LinkedIn facebook twitter youtube
News archive
Recent news


DREAMM-2, the pivotal open-label, randomised study of two doses of belantamab mafodotin has reported a clinically meaningful overall response rate (ORR) in relapsed myeloma patients.

The 196 patients in the trial had relapsed myeloma, were refractory to an immunomodulatory drug, a proteasome inhibitor, and to treatment with an anti-CD38 antibody. The two-arm study met its primary objective and demonstrated a clinically meaningful overall response rate with belantamab mafodotin in the patient population, according to a press release from GlaxoSmithKline (GSK). The safety and tolerability profile was consistent with that observed in DREAMM-1, the first-in-human study of belantamab mafodotin.

Safety and efficacy results from the DREAMM-2 study will be submitted for presentation at an upcoming scientific meeting. Additional ongoing studies are testing the effect of belantamab mafodotin as third-line monotherapy in relapsed/refractory myeloma and as a combination treatment in the first and second line setting as part of the broader DREAMM clinical development programme.



Recent news

» Daratumumab approved for first line treatment in Israel

» Join MPE's webinar on doctor and patients’ perspectives on myeloma CAR-T

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy